This inventor holds 1 USPTO granted patent. Top assignee: Mondobiotech Ag. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Lutz-Henning Block: Innovator in Hypertension Treatment
Introduction
Lutz-Henning Block is a notable inventor based in Emmendingen, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of hypertension. His innovative work focuses on the development of therapeutic peptides that can effectively address various forms of hypertension.
Latest Patents
Lutz-Henning Block holds a patent for "Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension." This invention relates to peptides that exhibit high biological and pharmacological activity as therapeutic drugs. These peptides are particularly useful in medical interventions that involve the dilation and remodeling of arterial blood vessels, both in pulmonary and systemic circulation. The patent highlights the importance of specific highly conservative amino acid residue sequences in the treatment of pulmonary and arteriolar hypertension. It has been demonstrated that naturally occurring peptides, such as vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP), are potent drugs for treating primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and systemic hypertension. Additionally, the patent discloses pharmaceutical compositions that are beneficial for treating these conditions.
Career Highlights
Lutz-Henning Block is associated with Mondobiotech AG, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on improving treatment options for patients suffering from hypertension-related diseases.
Collaborations
[This section has been skipped due to space constraints.]
Conclusion
Lutz-Henning Block's innovative contributions to hypertension treatment through his patented peptides represent a significant advancement in medical science. His work continues to pave the way for new therapeutic options that can improve patient outcomes in hypertension management.